A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

被引:0
作者
Mercedeh Ghadessi
Rui Tang
Joey Zhou
Rong Liu
Chenkun Wang
Kiichiro Toyoizumi
Chaoqun Mei
Lixia Zhang
C. Q. Deng
Robert A. Beckman
机构
[1] Data Science & Analytics,Biostatistics department
[2] Bayer U.S. LLC,Institute for Clinical and Translational Research, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health
[3] Pharmaceuticals,Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics
[4] Center of Excellence,undefined
[5] Methodology and Data Visualization,undefined
[6] Biostatistics Department,undefined
[7] Servier pharmaceuticals,undefined
[8] Biometrics,undefined
[9] Xcovery LLC,undefined
[10] Pharmaceuticals,undefined
[11] Bristol-Myers Squibb,undefined
[12] Vertex Pharmaceuticals,undefined
[13] Inc,undefined
[14] Biometrics,undefined
[15] Shionogi Inc,undefined
[16] University of Wisconsin-Madison,undefined
[17] Scipher Medicine,undefined
[18] United Therapeutic Corp,undefined
[19] Georgetown University Medical Center,undefined
来源
Orphanet Journal of Rare Diseases | / 15卷
关键词
Historical control; Clinical trial; Simulation; Sensitivity analysis; Rare disease; Pediatric indication; Real world data; Real world evidence;
D O I
暂无
中图分类号
学科分类号
摘要
Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs.
引用
收藏
相关论文
共 21 条
  • [1] Eichler HG(2016)“Threshold-crossing”: a useful way to establish the counterfactual in clinical trials? Clin Pharmacol Ther 100 699-712
  • [2] Bloechl-Daum B(2017)Bias from historical control groups used in orthodontic research: a metaepidemiological study Eur J Orthod 39 98-105
  • [3] Bauer P(2010)Summarizing historical information on controls in clinical trials Clin Trials 7 5-18
  • [4] Bretz F(2013)Use of historical control data for assessing treatment effects in clinical trials Pharm Stat [Internet] 13 41-54
  • [5] Brown J(2017)Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? Stat Med 36 899-916
  • [6] Hampson LV(1996)Basic methods for sensitivity analysis of bias Int J Epidemiol 25 1107-1115
  • [7] Papageorgiou SN(undefined)undefined undefined undefined undefined-undefined
  • [8] Koretsi V(undefined)undefined undefined undefined undefined-undefined
  • [9] Jäger A(undefined)undefined undefined undefined undefined-undefined
  • [10] Neuenschwander B(undefined)undefined undefined undefined undefined-undefined